Vaxcyte, Inc.
PCVX
$44.70
-$0.82-1.80%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -27.77% | -18.37% | -2.65% | -32.93% | 19.87% |
| Total Depreciation and Amortization | 4.17% | 2.36% | 1.86% | 6.55% | 29.13% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 379.46% | -64.75% | -18.37% | 168.45% | -25.08% |
| Change in Net Operating Assets | -4.80% | 168.04% | -1,892.56% | -108.51% | 474.90% |
| Cash from Operations | -18.27% | 27.13% | -49.26% | -83.50% | 49.99% |
| Capital Expenditure | -23.49% | 63.53% | 10.91% | 21.15% | 2.31% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 52.25% | -41.70% | 128.47% | 40.03% | -2,021.71% |
| Cash from Investing | 55.86% | -36.96% | 122.13% | 39.24% | -1,040.49% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -90.54% | -46.52% | 0.95% | -99.61% | 1,274.14% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -454.67% | 86.45% | -387.56% | 88.38% | -1,552.39% |
| Cash from Financing | -245.79% | 231.75% | -84.53% | -99.68% | 1,272.71% |
| Foreign Exchange rate Adjustments | -63.63% | -31.74% | -13.19% | 124.21% | -295.46% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 36.38% | 2.24% | 93.81% | -224.56% | 672.73% |